Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria–type cells in bone marrow failure syndrome

Wang, Hongbo; Chuhjo, Tatsuya; Yasue, Shizuka; Omine, Mitsuhiro; Nakao, Shinji

doi:10.1182/blood-2002-03-0799

Cited by 200 publications

(196 citation statements)

References 32 publications

Supporting

Mentioning

174

Contrasting

Unclassified

Order By: Relevance

“…We previous demonstrated the frequency of HLA-DR15 to markedly increase in patients with MDS-refractory anemia (RA) and a small population of PNH-type cells (more than 0.003% for granulocyte, more than 0.005% for RBCs), as demonstrated by sensitive flow cytometry [13]. In that study, RA patients possessing a small population of PNH-type cells displayed favorable responses to CsA.…”

Section: Introductionmentioning

confidence: 94%

Roles of DRB1∗1501 and DRB1∗1502 in the pathogenesis of aplastic anemia

Sugimori

Yamazaki

Feng

et al. 2007

Experimental Hematology

Self Cite

View full text Add to dashboard Cite

Category Clinical investigations Word countsTotal text word count: 3412 words Abstract word count: 240 words 2 ABSTRACTObjective. Although a number of reports have documented a significantly increased incidence of HLA-DR15 in aplastic anemia (AA), the exact role of HLA-DR15 in the immune mechanisms of AA remains unclear. We herein clarify the difference between DRB1*1501 and DRB1*1502, the 2 DRB1 alleles which determine the presentation of HLA-DR15, in the pathophysiology of AA. Materials and Methods.We investigated the relationships of the patients' HLA-DRB1 allele with both the presence of a small population of CD55 -CD59 -(PNH-type) blood cells and the response to antithymocyte globulin (ATG) plus cyclosporine (CsA) therapy in 140 Japanese AA patients. Results. Of the 30 different DRB1 alleles, only DRB1*1501 (33.6% vs. 12.8%, P c <0.01) and DRB1*1502 (43.6% vs. 24.4%, P c <0.01) displayed significantly higher frequencies among the AA patients than among a control. AA patients possessing HLA-DR15 tended to be old, and especially, the frequency of DRB1*1502 in patients ≥40 years old (52.4%) was markedly higher than that in those <40 years old (16.2%, P c <0.01). Only DRB1*1501 was significantly associated with the presence of a small population of PNH-type cells and it also showed a good response to ATG plus CsA therapy in a univariate analysis. A multivariate analysis showed only the presence of a small population of PNH-type cells to be a significant factor associated with a good response to the immunosuppressive therapy (P<0.01). Conclusion.Although both DRB1*1501 and DRB1*1502 contribute to the development of AA, the methods of contribution differ between the two alleles.3

show abstract

Section: Introductionmentioning

confidence: 94%

Roles of DRB1∗1501 and DRB1∗1502 in the pathogenesis of aplastic anemia

Sugimori

Yamazaki

Feng

et al. 2007

Experimental Hematology

Self Cite

View full text Add to dashboard Cite

show abstract

“…These observations and the fact that many AA patients have minor GPI-AP deficient cells at diagnosis or emergence after immunosuppressive therapy [8][9][10][11][12][13][26][27][28] was the reason for us to investigate the antibody composition of ATG to GPI-anchored proteins. Indeed we could demonstrate the presence of high concentrations of CD52 antibodies and, somewhat lower, CD48 antibodies in all ATG products.…”

Section: Discussionmentioning

confidence: 99%

Antibodies to glycosylphosphatidyl-inositol anchored proteins (GPI-AP) in antithymocyte and antilymphocyte globulin: possible role for the expansion of GPI-AP deficient cells in aplastic anemia

2009

View full text Add to dashboard Cite

Antithymocyte globulin (ATG) and antilymphocyte globulin (ALG) are currently used successfully for immunosuppressive treatment of aplastic anemia. In this study we have investigated whether commercial ATG/ALG preparations contain antibodies against glycosylphosphatidyl-inositol anchored proteins (GPI-AP), which could be responsible for emergence of GPI-deficient populations in aplastic anemia after ATG/ALG therapy. We analyzed four commercial ATG/

show abstract

“…Presence of the PNH phenotype has been associated with a greater probability of response to cyclosporine and ATG therapy. 58,59 Addition of cyclosporine and/or steroids to ATG does not appear to improve response rates any further. 38 Problems with serum sickness and other toxicities may be significant with ATG and ALG, especially in older patients, empha- sizing the need to select patients carefully for these treatment modalities.…”

Section: Immunomodulationmentioning

confidence: 99%

Novel therapies for myelodysplastic syndromes

Faderl

Kantarjian

2004

Cancer

View full text Add to dashboard Cite

BACKGROUND.The assessment of patients with myelodysplastic syndromes (MDS) and the choice of therapies remain challenging. New therapies are now emerging after the identification of molecular targets that result in improvement of hematologic parameters and may hold promise for the prevention of disease progression. METHODS.A review of the English literature was performed that included original articles and related reviews from MEDLINE (PubMed) and abstracts based on published meeting material. RESULTS.MDS is a heterogeneous group of disorders. Although current classification and prognostic schemes have proven valid to define subgroups, they are insufficient to take into consideration the significant biologic diversity of MDS.

show abstract

Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria–type cells in bone marrow failure syndrome

Cited by 200 publications

References 32 publications

Roles of DRB1∗1501 and DRB1∗1502 in the pathogenesis of aplastic anemia

Roles of DRB1∗1501 and DRB1∗1502 in the pathogenesis of aplastic anemia

Antibodies to glycosylphosphatidyl-inositol anchored proteins (GPI-AP) in antithymocyte and antilymphocyte globulin: possible role for the expansion of GPI-AP deficient cells in aplastic anemia

Novel therapies for myelodysplastic syndromes

Contact Info

Product

Resources

About